Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

BD Medical’s pen needle launch makes injections easier for diabetics

BD Medical, a division of Becton, Dickinson and Company, has launched the BD Ultra-Fine Nano 4mm Pen Needle with EasyFlow Technology in US.

Making the procedure fast and easy, EasyFlow Technology helps patients in injecting insulin each day by themselves.

Insulin is used as a life-saving drug to control the sugar levels in the blood. Several patients suffering with diabetes need to take the medication for the rest of their lives, often with multiple injections each day.

People with diabetes recognize the impact of BD’s latest innovation on their daily injection experience, with a majority preferring BD Ultra-Fine Nano 4mm Pen Needles with EasyFlow Technology to their current pen needle on all three of the leading insulin pen brands, the company claimed.

A clinical study, which was published in Clinical Therapeutics, showed that 61% of patients reported they needed less thumb force to inject, and 49% of patients reported less time to inject than with their usual pen needle.

BD claimed that it has been able to deliver improved performance by increasing the space inside the needle while maintaining industry leading gauge size – increasing the flow rate in controlled laboratory testing by up to 149% versus competitive pen needles.

Recently, the company launched PentaPoint Comfort, a patented five-bevel needle tip that has been clinically proven to enhance comfort.

Both of these launches are now part of BD’s shortest and thinnest pen needle, the BD Ultra-Fine Nano 4mm Pen Needle.

BD Medical Diabetes Care Linda Tharby said, "Building on the introduction of BD’s 4mm needle and 5-bevel PentaPoint Comfort design, we are confident that our new EasyFlow Technology will provide the most comfortable injection experience to help enable patients to adhere more easily to their therapy regimens and ultimately improve their outcomes."

Currently, EasyFlow Technology exists in the US and Canada and the company is planning to make the technology available in European countries soon.